BeOne Medicines showcases oncology pipeline

In a significant showcase for investors, BeOne Medicines (Nasdaq: ONC; HKEX: 06160) announced major advancements to its industry-leading oncology pipeline during an investor R&D Day. The event comes at a pivotal moment for the company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition.

“At BeOne, our mission is simple yet bold: to create the world’s first next-generation oncology company,” said John Oyler, co-founder, chairman and chied executive of BeOne, previously known as BeiGene. “From our innovative discovery engine to one of the broadest pipelines in oncology, we are well-positioned to bring transformative medicines to patients worldwide - and to do so with speed, quality, and purpose,” he added.

In hematologic cancers, BeOne’s program is driven by its wholly-owned assets including Brukinsa (zanubrutinib), a second-generation covalent BTK inhibitor and the backbone of the hematology franchise, sonrotoclax, a potential best-in-class next-generation BCL2 inhibitor, and BGB-16673, a BTK CDAC. New clinical data from CaDAnCe-101 highlight the promise of BGB-16673, a potential first in-class BTK degrader, for patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL).